Delivery Order HHSN261201200034I-HHSN26100003
Award Date 9/20/13
Potential Completion Date 3/19/20
Potential Value $1.3M
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Houston, TX 77230, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Cancer Institute issued a delivery order to The University of Texas M.D. Anderson Cancer Center on September 20, 2013, with a ceiling value of $999,843.18 under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for a randomized Phase II trial of low-dose aspirin versus placebo in high-risk individuals with CT screen-detected lung nodules. The Cancer Prevention Agent Development Program is an NCI indefinite delivery contract supporting early-phase clinical research in...
- The National Cancer Institute issued a delivery order to The University of Texas MD Anderson Cancer Center on September 24, 2015, with a ceiling value of $4.2 million under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support of early-phase clinical research. Place of performance is Houston, TX. The order is priced on a cost-no-fee basis with an ultimate completion date of September 23, 2019. This delivery order represents Option 2 core infrastructure...
- The University of Texas M.D. Anderson Cancer Center has been awarded a $632,712 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for the task of conducting preclinical efficacy and intermediate biomarker studies to develop an induced pluripotent stem cell-based vaccine for the...
- This is a firm fixed-price delivery order contract awarded by the Department of Health and Human Services, National Institutes of Health, National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $979,494.00, is for research to determine dosing regimens of the drug erlotinib in combination with sulindac for the prevention of colorectal cancer while reducing agent toxicity. The research is part of the...
- The National Cancer Institute issued a delivery order to The University of Texas M.D. Anderson Cancer Center on June 15, 2015, with a ceiling value of $846,288.93, for a clinical prevention research study examining the effect of aspirin on biomarkers of Barrett's esophagus after successful eradication with radiofrequency ablation. This delivery order was issued under the Cancer Prevention Agent Development Program 2012-2017 IDIQ. Place of performance is Houston, TX. The order ultimate completion...
- The National Cancer Institute issued a $1,293,012 delivery order to The University of Texas MD Anderson Cancer Center on July 26, 2023, for further development of an induced pluripotent stem cell (iPSC)-based vaccine for colon cancer prevention, with completion scheduled for December 25, 2026. This delivery order is issued under the PREVENT Preclinical Drug Development Program (PREVENT), a $149,995,000 National Cancer Institute IDIQ supporting preclinical efficacy testing and biomarker...
- This is a delivery order issued under the National Cancer Institute's Cancer Prevention Agent Development Program 2012-2017 indefinite delivery/indefinite quantity (IDIQ) contract. The contract was awarded to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to provide core infrastructure support for the program. The award has a ceiling value of $725,737.89 and an ultimate completion date of September 23, 2015. The contract is a cost-no-fee type...
- This is a firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center (MD Anderson) in the amount of $400,411.43. The contract was issued under the PREVENT Cancer Program (PREVENT) contract vehicle and supports the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS project with a period of performance through...
- The National Cancer Institute issued a $1.121 million delivery order to The University of Texas MD Anderson Cancer Center on June 1, 2022, under the PREVENT Preclinical Drug Development Program (PREVENT) IDIQ for preclinical efficacy and biomarker evaluation targeting the PARP pathway for breast cancer prevention. PREVENT is a $149.995 million multiple-award IDIQ contract active through January 24, 2029, supporting comprehensive evaluation of potential cancer preventive agents through...
- This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The $633,898 firm fixed price delivery order is part of NCI's "Preclinical Agent Development Assays 2012-2016" indefinite delivery contract and supports research on the use of the drug naproxen for the prevention of colorectal cancer. The contract does not have a small business set-aside...